A. V. von Eschenbach

发表

American Cancer Society guideline for the early detection of prostate cancer: Update 1997

G. Murphy, A. V. von Eschenbach, R. Ho, 1997, CA: a cancer journal for clinicians.

American Cancer Society Guidelines for the Early Detection of Cancer

B. Levin, D. Saslow, S. Sener, 2002, CA: a cancer journal for clinicians.

Identification of p53 gene mutations in bladder cancers and urine samples.

P. Green, B. Vogelstein, F. Marshall, 1991, Science.

Acridine‐orange flow cytometry of urinary bladder washings for the detection of transitional cell carcinoma of the bladder: The influence of prior local therapy

B. Barlogie, A. V. von Eschenbach, R. Katz, 1987, Cancer.

Cancer Informatics Vision: caBIG™

K. Buetow, A. V. von Eschenbach, 2006, Cancer informatics.

Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer.

L. Chung, A. V. von Eschenbach, S. Pathak, 1994, Cancer research.

Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer.

G Starkschall, J A Antolak, A Pollack, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial.

George Starkschall, K., Alan Pollack, 2002, International journal of radiation oncology, biology, physics.

Roundtable--the changing oncology landscape: evolution or revolution?

C. Goodman, R. Beveridge, J. Mahoney, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Improved survival with cyclic chemotherapy for nonseminomatous germ cell tumors of the testis.

C. Logothetis, A. V. von Eschenbach, D. Johnson, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer.

L. Chung, A. V. von Eschenbach, R. Sikes, 1996, Journal of the National Cancer Institute.

Frequency and characterization of p53 mutations in clinically localized prostate cancer.

P. Troncoso, L. Chung, A. V. von Eschenbach, 1995, Urology.

Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells.

M. Campbell, T. McDonnell, A. V. von Eschenbach, 1995, Cancer letters.

Sentinel lymph node dissection for penile carcinoma: the M. D. Anderson Cancer Center experience.

C. Dinney, A. V. von Eschenbach, C. Pettaway, 1995, The Journal of urology.

Therapy of spontaneous lung metastasis of murine renal adenocarcinoma by systemic administration of liposomes containing the macrophage activator CGP 31362.

C. Bucana, C. Dinney, I. Fidler, 1991, Cancer research.

Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice.

I. Fidler, A. V. von Eschenbach, S. Naito, 1986, Cancer research.

Patterns of human tumor-infiltrating lymphocytes in 120 human cancers.

C. Balch, A. V. von Eschenbach, L. Riley, 1990, Archives of surgery.

Lack of prostate cancer radiosensitization by androgen deprivation.

A. V. von Eschenbach, F. Ashoori, A. Pollack, 2001, International journal of radiation oncology, biology, physics.

Serum testosterone--a significant determinant of metastatic relapse for irradiated localized prostate cancer.

A. V. von Eschenbach, A. Pollack, G. Zagars, 1997, Urology.

The early supra-additive apoptotic response of R3327-G prostate tumors to androgen ablation and radiation is not sustained with multiple fractions.

A. V. von Eschenbach, F. Ashoori, A. Pollack, 2000, International journal of radiation oncology, biology, physics.

Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long-term results of a prospective randomized study.

A. V. von Eschenbach, D. Hussey, G. Zagars, 1988, International journal of radiation oncology, biology, physics.

Amplification and expression of the c‐erb B‐2/neu proto‐oncogene in human bladder cancer

M. Hung, A. V. von Eschenbach, J. Ro, 1990, Molecular carcinogenesis.

Progress with a purpose: eliminating suffering and death due to cancer.

A. V. von Eschenbach, 2006, Oncology.

Specific histologic and cytogenetic evidence for in vivo malignant transformation of murine host cells by three human prostate cancer cell lines.

A. Multani, L. Chung, A. V. von Eschenbach, 1997, Oncology research.

Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts.

M. Gleave, L. Chung, A. V. von Eschenbach, 1991, Cancer research.

Can cancer cells transform normal host cells into malignant cells?

A. Multani, L. Chung, A. V. von Eschenbach, 1997, British Journal of Cancer.

Expression of c‐erb B‐2/neu proto‐oncogene in human prostatic cancer tissues and cell lines

G. Miller, A. V. von Eschenbach, H. Zhau, 1992, Molecular carcinogenesis.

Small cell carcinoma of prostate associated with myasthenic (Eaton-Lambert) syndrome.

B. Têtu, C. Logothetis, A. V. von Eschenbach, 1989, Urology.

Salvage cystectomy for bladder carcinoma

A. V. von Eschenbach, D. Swanson, R. Bracken, 1981, Cancer.

Preoperative radiotherapy for muscle‐invasive bladder carcinoma. Long term follow‐up and prognostic factors for 338 patients

C. Dinney, A. V. von Eschenbach, A. Pollack, 1994, Cancer.

Local control of muscle-invasive bladder cancer: preoperative radiotherapy and cystectomy versus cystectomy alone.

C. Dinney, A. V. von Eschenbach, A. Pollack, 1995, International journal of radiation oncology, biology, physics.

Relationship of Ki‐67 labeling index to DNA‐ploidy, S‐phase fraction, and outcome in prostate cancer treated with radiotherapy

V. Khoo, P. Troncoso, A. V. von Eschenbach, 1999, The Prostate.

Gleason grade and other prognostic factors--response to Drs. Hammond and Grignon.

A. V. von Eschenbach, A. Pollack, G. Zagars, 1995, International journal of radiation oncology, biology, physics.

The prognostic importance of Gleason grade in prostatic adenocarcinoma: a long-term follow-up study of 648 patients treated with radiation therapy.

A. V. von Eschenbach, A. Pollack, G. Zagars, 1995, International journal of radiation oncology, biology, physics.

Application of a tumor suppressor (C-CAM1)-expressing recombinant adenovirus in androgen-independent human prostate cancer therapy: a preclinical study.

S. H. Lin, A. V. von Eschenbach, W. Zhang, 1995, Cancer research.

The Biomarkers Consortium: public and private sectors working in partnership to improve the public health.

E. Zerhouni, A. V. von Eschenbach, Charles A. Sanders, 2007, The Oncologist.

p53 protein accumulation and gene mutation in the progression of human prostate carcinoma.

W. W. Nichols, P. Troncoso, A. V. von Eschenbach, 1993, Journal of the National Cancer Institute.

American Cancer Society Guidelines for the Early Detection of Cancer: Update of Early Detection Guidelines for Prostate, Colorectal, and Endometrial Cancers: ALSO: Update 2001—Testing for Early Lung Cancer Detection

R Wender, T. Byers, B. Levin, 2001, CA: a cancer journal for clinicians.

NCI sets goal of eliminating suffering and death due to cancer by 2015.

A. V. von Eschenbach, Andrew C von Eschenbach, 2003, Journal of the National Medical Association.

Regulation of Gelatinase Production in Metastatic Renal Cell Carcinoma by Organ‐specific Fibroblasts

C. Bucana, T. Tsuruo, I. Fidler, 1994, Japanese journal of cancer research : Gann.

The prognostic significance of DNA ploidy in clinically localized prostate cancer treated with radiation therapy.

A. El‐Naggar, A. V. von Eschenbach, A. Pollack, 1994, International journal of radiation oncology, biology, physics.

Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline.

M. Gleave, L. Chung, A. V. von Eschenbach, 1993, Cancer research.

Identifying patients with low-risk clinical stage I nonseminomatous testicular tumors who should be treated by surveillance.

R. Babaian, A. V. von Eschenbach, C. Dunphy, 1989, Urology.

Original Articles: Bladder Cancer: Management of Transitional Cell Carcinoma Involving Von Brunn's Nests

C. Dinney, R. Babaian, A. V. von Eschenbach, 1995 .

The role of radiation therapy in stages A2 and B adenocarcinoma of the prostate.

A. V. von Eschenbach, G. Zagars, D. Johnson, 1988, International journal of radiation oncology, biology, physics.

Ki-67 staining is an independent correlate of biochemical failure in prostate cancer treated with radiotherapy.

V. Khoo, P. Troncoso, A. V. von Eschenbach, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Radioimmunological imaging of metastatic prostatic cancer with 111indium-labeled monoclonal antibody PAY 276.

D. Carlo, J. Murray, R. Babaian, 1987, The Journal of urology.

Human prostate cancer model: Roles of growth factors and extracellular matrices

M. Gleave, J. Rubin, C. Logothetis, 1992, Journal of cellular biochemistry. Supplement.

Evidence for metastatic heterogeneity of human renal cell carcinoma.

I. Fidler, A. V. von Eschenbach, S. Naito, 1988, Anticancer research.

Different growth pattern and biologic behavior of human renal cell carcinoma implanted into different organs of nude mice.

I. Fidler, A. V. von Eschenbach, S. Naito, 1987, Journal of the National Cancer Institute.

Human recombinant interferons‐beta and ‐gamma decrease gelatinase production and invasion by human KG‐2 renal‐carcinoma cells

T. Tsuruo, I. Fidler, A. V. von Eschenbach, 1994, International journal of cancer.

In vivo modulation of macrophage tumoricidal activity by oral administration of the liposome-encapsulated macrophage activator CGP 19835A.

C. Bucana, I. Fidler, A. V. von Eschenbach, 1994, Cancer research.

Stage C adenocarcinoma of the prostate. An analysis of 551 patients treated with external beam radiation

A. V. von Eschenbach, G. Zagars, M. Oswald, 1987, Cancer.

Ketoconazole therapy for hormonally refractive metastatic prostate cancer.

R. Babaian, A. V. von Eschenbach, K. Wishnow, 1988, Urology.

Primary chemotherapy for clinical stage II nonseminomatous germ cell tumors of the testis: a follow-up of 50 patients.

C. Logothetis, A. V. von Eschenbach, D. Johnson, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lymphangiography in genitourinary cancer.

S. Wallace, A. V. von Eschenbach, B. Jing, 1985, The Urologic clinics of North America.

Major surgery to manage definitively severe complications of salvage cryotherapy for prostate cancer.

J. Skibber, A. V. von Eschenbach, L. Pisters, 2000, The Journal of urology.

Cancer Informatics Vision: caBIG™

K. Buetow, A. V. von Eschenbach, 2006, Cancer informatics.

Epidemiologic determinants of clinically relevant prostate cancer

M. Spitz, P. Scardino, C. Amos, 2000, International journal of cancer.

Prostatic intraepithelial neoplasia and invasive prostatic adenocarcinoma in cystoprostatectomy specimens.

D. Grignon, P. Troncoso, R. Babaian, 1989, Urology.

Sexual and marital relationships after radiotherapy for seminoma.

L. Schover, A. V. von Eschenbach, A. C. Eschenbach, 1986, Urology.

Telomeric DNA: Marker for human prostate cancer development?

R. Datar, A. Multani, L. Chung, 1998, The Prostate.

Continuous infusion of vinblastine for advanced hormone-refractory prostate cancer.

C. Logothetis, A. V. von Eschenbach, M. Samuels, 1985, Cancer treatment reports.

Cyclic chemotherapy with cyclophosphamide, doxorubicin, and cisplatin plus vinblastine and bleomycin in advanced germinal tumors. Results with 100 patients.

C. Logothetis, A. V. von Eschenbach, D. Johnson, 1986, The American journal of medicine.

Primary chemotherapy followed by a selective retroperitoneal lymphadenectomy in the management of clinical stage II testicular carcinoma: a preliminary report.

C. Logothetis, A. V. von Eschenbach, D. Johnson, 1985, The Journal of urology.

Orchiectomy in advanced germ cell cancer following intensive chemotherapy: a comparison of systemic to testicular response.

C. Logothetis, A. V. von Eschenbach, A. Ayala, 1986, The Journal of urology.

Adjuvant chemotherapy of bladder cancer: a preliminary report.

C. Logothetis, A. V. von Eschenbach, D. Johnson, 1988, The Journal of urology.

Chemotherapy of extragonadal germ cell tumors.

C. Logothetis, A. V. von Eschenbach, D. Johnson, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Successful treatment of pure endodermal sinus tumors in adult men.

C. Logothetis, A. V. von Eschenbach, A. Ayala, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Spermatic cord sarcoma: outcome, patterns of failure and management.

M. Ballo, B. Feig, P. Pisters, 2001, The Journal of urology.

Structural alterations of chromosome 5 in twelve human prostate cancer cell lines.

P. Troncoso, C. Logothetis, A. Multani, 1998, Cancer genetics and cytogenetics.

Human renal‐cell carcinoma cells are able to activate natural killer cells

A. V. von Eschenbach, K. Itoh, K. Hayakawa, 1992, International journal of cancer.

Immunotherapy of murine renal adenocarcinoma by systemic administration of liposomes containing the synthetic macrophage activator CGP 31362 or CGP 19835A in combination with interleukin 2 or gamma-interferon.

C. Dinney, I. Fidler, A. V. von Eschenbach, 1992, Cancer research.

Sex therapy and the penile prosthesis: a synthesis.

L. Schover, A. V. von Eschenbach, 1985, Journal of sex & marital therapy.

Sexual rehabilitation and male radical cystectomy.

L. Schover, A. V. von Eschenbach, R. Evans, 1986, The Journal of urology.

Early androgen ablation for stage D1 (N1 to N3, M0) prostate cancer: prognostic variables and outcome.

A. V. von Eschenbach, A. Pollack, G. Zagars, 1994, The Journal of urology.

Clonal analysis of lymphocytes from tumor, peripheral blood, and nontumorous kidney in primary renal cell carcinoma.

C. Balch, A. V. von Eschenbach, D. Parkinson, 1990, Cancer research.

Sexual rehabilitation of urologic cancer patients: A practical approach

L. Schover, A. V. von Eschenbach, Dorothy B. Smith, 1984, CA: a cancer journal for clinicians.

Cyclophosphamide, doxorubicin and cisplatin chemotherapy for patients with locally advanced urothelial tumors with or without nodal metastases.

C. Logothetis, A. V. von Eschenbach, D. Johnson, 1985, The Journal of urology.

Immunoperoxidase localization of prostatic acid phosphatase in prostatic carcinoma with sarcomatoid changes.

A. V. von Eschenbach, N. Ordóñez, A. Ayala, 1982, Urology.

Study of Tumor-Infiltrating Lymphocytes for Adoptive Therapy of Renal Cell Carcinoma (RCC) and Metastatic Melanoma: Sequential Proliferation of Cytotoxic Natural Killer and Noncytotoxic T Cells in RCC

A. V. von Eschenbach, S. Legha, D. Parkinson, 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy.

Hormonal therapy for prostate cancer.

A. V. von Eschenbach, A. Rosenberg, 1990, Seminars in surgical oncology.

Bladder perforation resulting from the use of the neodymium: YAG laser

A. V. von Eschenbach, F. Greskovich, 1991, Lasers in surgery and medicine.

Mediastinal metastases from prostatic carcinoma.

H. Libshitz, A. V. von Eschenbach, M. M. Lindell, 1982, The Journal of urology.

Surveillance alone for patients with clinical stage I nonseminomatous germ cell tumors of the testis: preliminary results.

A. V. von Eschenbach, D. Johnson, D. Swanson, 1984, The Journal of urology.

The significance of DNA‐ploidy and S‐phase fraction in node‐positive (stage D1) prostate cancer treated with androgen ablation

P. Troncoso, A. V. von Eschenbach, A. Pollack, 1997, The Prostate.

Correlation of non-random chromosomal aberrations in lymphocytes of prostate cancer patients with specific clinical parameters.

D. Johnston, R. Babaian, C. Logothetis, 2000, International journal of oncology.

Lymphangiography in staging of carcinoma of the prostate: the potential value of percutaneous lymph node biopsy.

S. Wallace, A. V. von Eschenbach, D. Hussey, 1979, Radiology.

Angioinfarction plus nephrectomy for metastatic renal cell carcinoma--an update.

S. Wallace, A. V. von Eschenbach, D. Johnson, 1983, The Journal of urology.

Untreated prostatic carcinoma is not associated with frequent thrombohemorrhagic disorders.

A. V. von Eschenbach, B. Drewinko, V. Guinee, 1987, Urology.

Therapy and prognosis for male anterior urethral carcinoma: an update.

C. Dinney, R. Babaian, A. V. von Eschenbach, 1994, Urology.

Prostate and bone fibroblasts induce human prostate cancer growth in vivo: implications for bidirectional tumor-stromal cell interaction in prostate carcinoma growth and metastasis.

M. Gleave, L. Chung, A. V. von Eschenbach, 1992, The Journal of urology.

Predictive value of prostate specific antigen nadir after salvage cryotherapy.

A. V. von Eschenbach, L. Pisters, G. Greene, 1998, The Journal of urology.

Treatment options for localized recurrence of prostate cancer following radiation therapy.

A. V. von Eschenbach, L. Pisters, D. Corral, 1996, The Urologic clinics of North America.

Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen.

A. V. von Eschenbach, A. Pollack, G. Zagars, 1995, International journal of radiation oncology, biology, physics.

The source of pretreatment serum prostate-specific antigen in clinically localized prostate cancer--T, N, or M?

A. V. von Eschenbach, A. Pollack, V. Kavadi, 1995, International journal of radiation oncology, biology, physics.

Early detection program for prostate cancer: results and identification of high-risk patient population.

R. Babaian, A. V. von Eschenbach, A C von Eschenbach, 1991, Urology.

Role of intravesical mitomycin C in management of superficial bladder tumors.

A. V. von Eschenbach, S. Crooke, D. Johnson, 1980, Urology.

Renal cell carcinoma with acrometastasis: report of two cases and review of the literature.

D. Grignon, A. V. von Eschenbach, J. Ro, 1991, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

c-met proto-oncogene expression in benign and malignant human prostate tissues.

P. Troncoso, L. Chung, A. V. von Eschenbach, 1995, The Journal of urology.

Model Systems of Prostate Cancer: Uses and Limitations

Christopher J. Logothetis, Andrew C. von Eschenbach, P. Troncoso, 1998, Cancer and Metastasis Reviews.

Histologic grading study of prostate adenocarcinoma: The development of a new system and comparison with other methods—A preliminary study

D E Johnson, A. V. von Eschenbach, D. Hussey, 1982, Cancer.

Binding of liposomes to human bladder tumor epithelial cell lines: implications for an intravesical drug delivery system for the treatment of bladder cancer.

I. Fidler, A. V. von Eschenbach, R. Nayar, 1989, Selective cancer therapeutics.

Prostatic carcinogenesis evoked by cellular interaction.

L. Chung, A. V. von Eschenbach, J. Ro, 1988, Environmental health perspectives.

Sexual and marital relationships after treatment for nonseminomatous testicular cancer.

L. Schover, A. V. von Eschenbach, A. C. Eschenbach, 1985, Urology.

Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer.

C. Logothetis, A. V. von Eschenbach, D. Johnson, 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique.

C. Bucana, I. Fidler, A. V. von Eschenbach, 1997, The American journal of pathology.

The development of liposomes containing interferon alpha for the intravesical therapy of human superficial bladder cancer.

I. Fidler, A. V. von Eschenbach, D. Fan, 1990, The Journal of urology.

Fibroblast-mediated acceleration of human epithelial tumor growth in vivo.

T. Hsu, L. Chung, M. Freeman, 1990, Proceedings of the National Academy of Sciences of the United States of America.

Apoptosis suppression by bcl-2 is correlated with the regulation of nuclear and cytosolic Ca2+.

T. McDonnell, A. V. von Eschenbach, D. McConkey, 1996, Oncogene.

Prostate‐specific antigen. An important marker for prostate cancer treated by external beam radiation therapy

A. V. von Eschenbach, G. Zagars, 1993, Cancer.

p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential.

P. Troncoso, C. Logothetis, A. V. von Eschenbach, 1999, The Journal of urology.

Expression of bcl-2 oncoprotein and p53 protein accumulation in bone marrow metastases of androgen independent prostate cancer.

T. McDonnell, P. Troncoso, C. Logothetis, 1997, The Journal of urology.

The T classification of clinically localized prostate cancer. An appraisal based on disease outcome after radiation therapy

A. V. von Eschenbach, A. Pollack, F. Geara, 1994, Cancer.

Clonal origin of bladder cancer.

B. Vogelstein, D. Sidransky, A. V. von Eschenbach, 1992, The New England journal of medicine.

Specific Androgen Receptor Activation by an Artificial Coactivator*

G. Jenster, A. V. von Eschenbach, K. Bramlett, 1999, The Journal of Biological Chemistry.

Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.

M. Gleave, L. Chung, A. V. von Eschenbach, 1992, Cancer research.

Co‐inoculation of tumorigenic rat prostate mesenchymal cells with non‐tumorigenic epithelial cells results in the development of carcinosarcoma in syngeneic and athymic animals

L. Chung, A. V. von Eschenbach, J. Ro, 1989, International journal of cancer.

Amplification of telomeric DNA directly correlates with metastatic potential of human and murine cancers of various histological origin.

S. Sen, I. Fidler, F. Ali-Osman, 1999, International journal of oncology.

Prostate-specific antigen and radiation therapy for clinically localized prostate cancer.

A Pollack, A. V. von Eschenbach, A. Pollack, 1995, International journal of radiation oncology, biology, physics.

Prognostic factors for clinically localized prostate carcinoma

A. V. von Eschenbach, A. Pollack, G. Zagars, 1997, Cancer.

Establishment of two human prostate cancer cell lines derived from a single bone metastasis.

D. Johnston, P. Troncoso, C. Logothetis, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

Homozygous deletions at 8p22 and 8p21 in prostate cancer implicate these regions as the sites for candidate tumor suppressor genes.

P. Troncoso, R. Babaian, A. V. von Eschenbach, 1995, Oncogene.

Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer.

A. V. von Eschenbach, A. Pollack, G. Zagars, 2001, Urology.

Regulation of lipid signaling pathways for cell survival and apoptosis by bcl-2 in prostate carcinoma cells.

T. McDonnell, A. V. von Eschenbach, D. Menter, 1997, Experimental cell research.

Serum prostate-specific antigen, clinical stage, pathologic grade, and the incidence of nodal metastases in prostate cancer.

A. V. von Eschenbach, A. Pollack, G. Zagars, 1994, Urology.

The influence of local control on metastatic dissemination of prostate cancer treated by external beam megavoltage radiation therapy

T. Schultheiss, A. V. von Eschenbach, G. Zagars, 1991, Cancer.

Quality of life after salvage cryotherapy: the impact of treatment parameters.

M. Litwin, A. V. von Eschenbach, L. Pisters, 1999, The Journal of urology.

Significance of tumor angiogenesis in clinically localized prostate carcinoma treated with external beam radiotherapy.

P. Troncoso, L. Chung, A. V. von Eschenbach, 1994, Urology.

Partial nephrectomy using the Nd:YAG Laser: A comparison of the 1.06 μ and 1.32 μ lasers employing different delivery systems

D. Grignon, A. V. von Eschenbach, K. Wishnow, 1988, Lasers in surgery and medicine.

Effective outpatient use of polyethylene glycol-electrolyte bowel preparation for radical cystectomy and ileal conduit urinary diversion.

R. Babaian, A. V. von Eschenbach, K. Wishnow, 1988, Urology.

External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era.

A. V. von Eschenbach, A. Pollack, L. Smith, 2000, International journal of radiation oncology, biology, physics.

Sexual function and female radical cystectomy: a case series.

L. Schover, A. V. von Eschenbach, 1985, The Journal of urology.

Sexual and marital counseling with men treated for testicular cancer.

L. Schover, A. V. von Eschenbach, 1984, Journal of sex & marital therapy.

Relationship of thyroid disease to renal cell carcinoma. An epidemiologic study.

A. V. von Eschenbach, D. Swanson, F. Dexeus, 1990, Urology.

Optimal delivery of perioperative chemotherapy: preliminary results of a randomized, prospective, comparative trial of preoperative and postoperative chemotherapy for invasive bladder carcinoma.

C. Dinney, C. Logothetis, A. V. von Eschenbach, 1996, The Journal of urology.

Prognostic factors in prostate cancer: Analysis of 874 patients treated with radiation therapy

A. V. von Eschenbach, G. Zagars, A. Ayala, 1993 .

Roles of lymphangiography and pelvic lymphadenectomy in staging prostate cancer.

A. V. von Eschenbach, D. Johnson, 1981, Urology.

Fine-needle percutaneous biopsy. A useful evaluation of lymph node metastasis from prostate cancer.

A. V. von Eschenbach, J. Zornoza, 1982, Urology.

A feasibility study of cryotherapy followed by radical prostatectomy for locally advanced prostate cancer.

C. Dinney, P. Troncoso, R. Babaian, 1999, The Journal of urology.

Consistent expression of an epithelial cell adhesion molecule (C-CAM) during human prostate development and loss of expression in prostate cancer: implication as a tumor suppressor.

Thomas, P. Troncoso, S. H. Lin, 1995, Cancer research.

Transrectal ultrasound-guided intraprostatic injection of absolute ethanol with and without carmustine: a feasibility study in the canine model.

A. V. von Eschenbach, L. Stephens, L. Pisters, 1999, Urology.

Proteins of human urine. II. Identification by two-dimensional electrophoresis of a new candidate marker for prostatic cancer.

J. J. Edwards, N. Anderson, A. V. von Eschenbach, 1982, Clinical chemistry.

The efficacy and complications of salvage cryotherapy of the prostate.

C. Dinney, R. Babaian, A. V. von Eschenbach, 1997, The Journal of urology.

The role of sexual rehabilitation in the treatment of patients with cancer

L. Schover, A. V. von Eschenbach, 1984, Cancer.

Consensus recommendations on how to assess the quality of surgical interventions

T. Pawlik, J. Barkun, J. Chiche, 2023, Nature Medicine.

Aneuploidy index in blood: a potential marker for early onset, androgen response, and metastasis in human prostate cancer.

D. Johnston, R. Babaian, C. Logothetis, 1999, Urology.

Molecular correlates of bcl-2-enhanced growth following androgen-ablation in prostate carcinoma cells in vivo.

T. McDonnell, M. Sarkiss, A. V. von Eschenbach, 1998, International journal of molecular medicine.

Salvage cryotherapy for recurrent prostate cancer after radiotherapy: variables affecting patient outcome.

A. V. von Eschenbach, L. Pisters, E. McGuire, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Incidence, extent and location of unsuspected pelvic lymph node metastasis in patients undergoing radical cystectomy for bladder cancer.

R. Babaian, A. V. von Eschenbach, K. Wishnow, 1987, The Journal of urology.

Molecular markers of outcome after radiotherapy in patients with prostate carcinoma

T. McDonnell, P. Troncoso, A. V. von Eschenbach, 2003, Cancer.

What are the risks of cystectomy and the advances in perioperative care?

J. Montie, N. Miyanaga, A. V. von Eschenbach, 1995, International journal of urology : official journal of the Japanese Urological Association.

Medical castration using megestrol acetate and minidose estrogen.

R. Babaian, A. V. von Eschenbach, K. Wishnow, 1988, Urology.

The challenge of prostate cancer

A. V. von Eschenbach, 1999, CA: a cancer journal for clinicians.

Denudation of the entire mucosa of the canine urinary bladder using the neodymium: YAG laser with the MTR 1.5 contact probe

D E Johnson, A. V. von Eschenbach, A G Ayala, 1988, Lasers in surgery and medicine.

Transrectal ultrasound for staging prostate carcinoma prior to radiation therapy

A. V. von Eschenbach, A. Pollack, F. Geara, 1999, Cancer.

Patient selection for salvage cryotherapy for locally recurrent prostate cancer after radiation therapy.

A. V. von Eschenbach, L. Pisters, P. Perrotte, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relationship of ultrasound staging and bilateral biopsy positivity to outcome in stage T1c prostate cancer treated with radiotherapy.

A. V. von Eschenbach, A. Pollack, G. Zagars, 1998, Urology.

Local tumor control with salvage cryotherapy for locally recurrent prostate cancer after external beam radiotherapy.

L. Levy, A. V. von Eschenbach, L. Pisters, 2001, The Journal of urology.

Spindling artifact of urothelial cells in post‐laser treatment urinary cytology

A. V. von Eschenbach, C. Fanning, S. Thomsen, 1993, Diagnostic Cytopathology.

Cryotherapy for renal cell carcinoma and angiomyolipoma.

B. Fornage, A. V. von Eschenbach, L. Pisters, 1996, The Journal of urology.

The neodymium-yttrium aluminum garnet (Nd:YAG) laser in urology.

A. V. von Eschenbach, 1986, Urologic clinics of North America.

Sutureless End‐to‐End bowel anastomosis using Nd:YAG and water‐soluble intralurninal stent

A. Costello, A. V. von Eschenbach, K. Wishnow, 1990 .

Long-term followup of incontinence and obstruction after salvage cryosurgical ablation of the prostate: results in 143 patients.

A. V. von Eschenbach, L. Pisters, A C von Eschenbach, 1997, The Journal of urology.

Code of ethics for the University of Texas System Cancer Center M.D. Anderson Hospital and Tumor Institute.

S. Reiser, A. V. von Eschenbach, J. van Eys, 1985, Texas medicine.

Cancer informatics vision: caBIG.

K. Buetow, A. V. von Eschenbach, 2007, Cancer Informatics.

The biologic dilemma of early carcinoma of the prostate.

A. V. von Eschenbach, 1996, Cancer.

Eliminating error-prone notations in medical communications

A. V. von Eschenbach, Andrew C von Eschenbach, 2007, Expert opinion on drug safety.

Health, Wealth, and the 21st Century Cures Act.

Andrew W Lo, A. Lo, T. Philipson, 2016, JAMA oncology.

The biologic dilemma of early carcinoma of the prostate

A. V. von Eschenbach, 2022 .

Exploration of new pathologic factors in terms of potential for prognostic significance and future applications.

P. Humphrey, G. Murphy, M. Brawer, 1996, Cancer.

Results of laser therapy for carcinoma of the penis: organ preservation.

R. Babaian, A. V. von Eschenbach, K. Wishnow, 1991, Progress in clinical and biological research.

NCI remains committed to current mammography guidelines.

A. V. von Eschenbach, Andrew C Von Eschenbach, 2002, The oncologist.